Michael Martin Breen - 04 Sep 2025 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Role
CEO and Director, Director
Signature
/s/ Michael Martin Breen
Issuer symbol
GTBP
Transactions as of
04 Sep 2025
Transactions value $
$0
Form type
4
Filing time
08 Sep 2025, 17:45:43 UTC
Previous filing
15 Aug 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Breen Michael Martin CEO and Director, Director C/O GT BIOPHARMA, INC., 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO /s/ Michael Martin Breen 08 Sep 2025 0001863633

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTBP Option to purchase Common Stock Award $0 +100,000 $0 100,000 04 Sep 2025 Common Stock 100,000 $1.33 Direct F1
transaction GTBP Option to purchase Common Stock Award $0 +100,000 $0 100,000 04 Sep 2025 Common Stock 100,000 $1.33 Direct F2
transaction GTBP Option to purchase Common Stock Award $0 +100,000 $0 100,000 04 Sep 2025 Common Stock 100,000 $1.33 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are fully vested and exercisable.
F2 The option vests in four equal quarterly installments beginning on January 1, 2025.
F3 The option vests in four equal quarterly installments beginning on January 1, 2026.